Diabetes Clinical Trials in Minneapolis

Showing 281-300 of 538 trials

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204

The primary objective of this protocol is to test the safety and efficacy of a treatment regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed by withdrawal of efalizumab and maintenance therapy with sirolimus, for the prevention of the destruction and rejection of islet transplants in type 1 diabetic recipients. Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U.S. market in April of 2009. Previously transplanted subjects have been transitioned to alternative immunosuppressives and no new subjects will be transplanted under this protocol.

Type 1 Diabetes MellitusHypoglycemia

University of Minnesota23 participantsStarted Nov 2007

Minneapolis, Minnesota, United States

COMPLETEDNA< 1 mile

Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation

NCT01945138

The purpose of this study is to determine the effectiveness of closed loop insulin pump therapy to control blood sugar following total pancreatectomy and islet auto-transplantation (TPIAT).

Chronic PancreatitisDiabetes Mellitus

University of Minnesota14 participantsStarted Feb 2014

Minneapolis, Minnesota, United States

COMPLETEDPhase 1< 1 mile

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

NCT01545570

This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers. The study will enrol approximately 72 subjects at one clinical study center in the United States.

Diabetes Mellitus, Type 2

GlaxoSmithKline82 participantsStarted Nov 2011

Minneapolis, Minnesota, United States

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

Diabetes Trials in Other Cities

First Time in Human Study Using GSK2330672

Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Metabolomic Analysis of Hepatic Insulin Resistance

Thiazolidinedione Intervention With Vitamin D Evaluation

Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics

Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Other Conditions in Minneapolis